Friedmann T, Roblin R. Gene therapy for human genetic disease? Science. 1972;175(4025):949–55. https://doi.org/10.1126/science.175.4025.949.

Article  CAS  PubMed  Google Scholar 

Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273–88. https://doi.org/10.1146/annurev-med-012017-043332.

Article  CAS  PubMed  Google Scholar 

Lehrman S. Virus treatment questioned after gene therapy death. Nature. 1999;401(6753):517–8. https://doi.org/10.1038/43977.

Article  CAS  PubMed  Google Scholar 

Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1–2:148–58.

Article  Google Scholar 

Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132–42. https://doi.org/10.1172/JCI35700.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415–9. https://doi.org/10.1126/science.1088547.

Article  CAS  PubMed  Google Scholar 

Hacein-Bey-Abina S, Von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X‑linked severe combined immunodeficiency. N Engl J Med. 2003;348(3):255–6. https://doi.org/10.1056/NEJM200301163480314.

Article  PubMed  Google Scholar 

Sibbald B. Death but one unintended consequence of gene-therapy trial. Cmaj. 2001;164(11):1612.

CAS  PubMed  PubMed Central  Google Scholar 

American Society of Gene. Cell Therapy. Gene, cell, + RNA Therapy Landscape Report Q3. Quarterly. 2023;. Data Report.

Rupp VM, Windisch M. Healthcare professionals in Austria are positive about gene therapy, but expressed a need for more topic related education. 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research, 21–24th February 2023, Frankfurt, Germany. Poster T‑16-04.

High KA, Therapy RMGG. N Engl J Med. 2019;381(5):455–64. https://doi.org/10.1056/NEJMra1706910.

Article  CAS  PubMed  Google Scholar 

Porteus MH. A new class of medicines through DNA editing. N Engl J Med. 2019;380(10):947–59. https://doi.org/10.1056/NEJMra1800729.

Article  CAS  PubMed  Google Scholar 

Summary of Product Characteristics Casgevy®

Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet. 211;12(5):301–15. https://doi.org/10.1038/nrg2985.

Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011;12(5):341–55. https://doi.org/10.1038/nrg2988.

Article  CAS  PubMed  Google Scholar 

Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018;359(6372):eaan4672. https://doi.org/10.1126/science.aan4672.

Article  CAS  PubMed  Google Scholar 

Wang D, Gau G. State-of-the-art human gene therapy: part I. Gene delivery technologies. Discov Med. 2014;18(97):67–77.

PubMed  PubMed Central  Google Scholar 

Kaufmann KB, Büning H, Galy A, Schambach A, Grez M. Gene therapy on the move. EMBO Mol Med. 2013;5(11):1642–61. https://doi.org/10.1002/emmm.201202287.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nathwani AC, Reiss U, Tuddenham E, Chowdary P, McIntosh J, Riddell A, et al. Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing “empty viral particles” on safety and efficacy of gene transfer. Blood. 2018;132(Supplement 1):491.

Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Ther. 1995;2(6):357–62.

CAS  PubMed  Google Scholar 

Muhuri M, Levy DI, Schulz M, McCarty D, Gao G. Durability of transgene expression after rAAV gene therapy. Mol Ther. 2022;30(4):1364–80. https://doi.org/10.1016/j.ymthe.2022.03.004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358–78. https://doi.org/10.1038/s41573-019-0012-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verdera HC, Kuranda K, Mingozzi F. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer. Mol Ther. 2020;28(3):723–46. https://doi.org/10.1016/j.ymthe.2019.12.010.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6(1):53. https://doi.org/10.1038/s41392-021-00487-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masat E, Pavani G, Mingozzi F. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. Discov Med. 2013;15(85):379–89.

PubMed  Google Scholar 

Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-Associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31(4):317–34. https://doi.org/10.1007/s40259-017-0234-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Issa SS, Shaimardanova AA, Solovyeva VV, Rizvanov AA. Various AAV serotypes and their applications in gene therapy: an overview. Cells. 2023;12(5):785. https://doi.org/10.3390/cells12050785.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lundstrom K. Viral vectors in gene therapy: Where do we stand in 2023? Viruses. 2023;15(3):698. https://doi.org/10.3390/v15030698.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li H, Malani N, Hamilton SR, Schlachterman A, Bussadori G, Edmonson SE, et al. Assessing the potential for AAV vector genotoxicity in a murine model. Blood. 2011;117(12):3311–9. https://doi.org/10.1182/blood-2010-08-302729.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wellman JA, Mingozzi F, Ozelo MC, Arruda V, Podsakoff G, Chen Y, et al. Results from long-term follow-up of severe hemophilia B subjects previously enrolled in a clinical study of AAV2-FIX gene transfer to the liver. Mol Ther. 2012;20:S28–9. https://doi.org/10.1016/S1525-0016(16)35873-7.

Weiller M, Coulibaly S, Gritsch H, Wang H, Rottensteiner H, Chuah MK, et al. Nonclinical safety evaluation of a next generation factor IX (FIX) gene therapy construct (SHP. Mice Haemophilia. 2019;64(8):138. https://doi.org/10.1111/hae.13810.

Article  Google Scholar 

Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341(6148):1233158. https://doi.org/10.1126/science.1233158.

Article  CAS  PubMed  Google Scholar 

Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil JA, Hongeng S, et al. Gene therapy in patients with transfusion-dependent beta-thalassemia. N Engl J Med. 2018;378(16):1479–93. https://doi.org/10.1056/NEJMoa1705342.

Article  CAS  PubMed  Google Scholar 

Summary of Product Characteristics Roctavian®.

Summary of Product Characteristics Hemgenix®.

Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118(9):3143–50. https://doi.org/10.1172/JCI35798.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, et al. Gene therapy for Wiskott-Aldrich syndrome—long-term efficacy and genotoxicity. Sci Transl Med. 2014;6(227):227ra33. https://doi.org/10.1126/scitranslmed.3007280.

Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al. Correction of X‑linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12(4):401–9. https://doi.org/10.1038/nm1393.

Article  CAS  PubMed  Google Scholar 

Fischer A, Hacein-Bey S, Cavazzana-Calvo M. Gene therapy of severe combined immunodeficiencies. Nat Rev Immuno. 2002;2(8):615–21. https://doi.org/10.1038/nri859.

Article  CAS  Google Scholar 

Nguyen GN, Everett JK, Kafle S, Roche AM, Raymond; HE, Leiby J, et al. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat Biotechnol. 2021;39(1):47–55. https://doi.org/10.1038/s41587-020-0741-7.

Chandler RJ, FaFave MC, Varshney GK, Trivedi NS, Carrillo-Carrasco N, Senac JS, et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. Clin Invest. 2015;125(2):870–80. https://doi.org/10.1172/JCI79213.

Article  Google Scholar 

Chandler RJ, Sands MS, Venditti CP. Recombinant adeno-associated virus integration and genotoxicity: Insights from animal models. Hum Gene Ther. 2017;28(4):314–22. https://doi.org/10.1089/hum.2017.009.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, Sands MS. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007;317(5837):477. h